Office of the Secretary 2007 – Federal Register Recent Federal Regulation Documents
Results 351 - 400 of 775
Revised Non-Foreign Overseas Per Diem Rates
The Per Diem, Travel and Transportation Allowance Committee is publishing Civilian Personnel Per Diem Bulletin Number 254. This bulletin lists revisions in the per diem rates prescribed for U.S. Government employees for official travel in Alaska, Hawaii, Puerto Rico, the Northern Mariana Islands and Possessions of the United States. AEA changes announced in Bulletin Number 194 remain in effect. Bulletin Number 254 is being published in the Federal Register to assure that travelers are paid per diem at the most current rates.
Sunshine Act Meeting
Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended), the Sunshine in the Government Act of 1976 (5 U.S.C. Sec. 552b, as amended) and 41 Code of Federal Regulations (CFR) Sec. Sec. 102-3.140 through 160, the Department of Defense announces the following committee meeting: Name of Committee: Department of Defense Task Force on the Future of Military Health Care, a duly established subcommittee of the Defense Health Board. Date of Meeting: July 11, 2007. Time of Meeting: 8:30 a.m. to 2 p.m. Place of Meeting: National Transportation Safety Board Conference Center, 429 L'Enfant Plaza, Washington, DC 20594. Purpose of Meeting: To obtain, review, and evaluate information related to the Task Force's congressionally-directed mission to examine matters relating to the future of military health care. The Task Force members will receive briefings on topics related to the delivery of military health care during the public meeting. Agenda: Discussion topics include Health and Wellness issues related to the military healthcare system. Prior to the public meeting the Task Force will conduct a Preparatory Work Meeting from 8 a.m.-8:20 a.m. to solely analyze relevant issues and facts in preparation for the Task Force's next public meeting. The Preparatory Work Meeting is closed to the public. Additional information is available online at the Task Force Web site: www.DoDfuturehealthcare.net.
Sunshine Act; Meeting of the President's Commission on Care for America's Returning Wounded Warriors
Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended), the Sunshine in the Government Act of 1976 (5 U.S.C. 552b, as amended) and 41 Code of Federal Regulations (CFR) Sec. Sec. 102-3.140 thorough 160, the Department of Defense announces the forthcoming public meeting: Name of Commission: President's Commission on Care for America's Returning Wounded Warriors (hereafter referred to as the Commission). Date of Meeting: July 16, 2007. Time of Meeting: 10 a.m. to (To Be Determined). Place of Meeting: Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC 20004. Purpose of Meeting: Review and evaluate the Commission's report and the findings and recommendations related to the Commission's mission to examine the care provided to wounded service members. Agenda: 9 a.m. to 9:45 a.m.Administrative Work Meeting (Not Open to the Public). 10 a.m.(Public Session). 10 a.m.Review and Evaluation of Commissions Findings and Recommendations. End: TBD. Subject to the availability of seating, this meeting is open to the public. The Commission will be discussing its final report and recommendations, consequently there will be no oral public forum. Any person desiring to make a written submission must provide the point of contact listed below with one (1) copy of the written submission by 11 July 2007 5 p.m. and one copy of any material intended for distribution at the meeting. Point of Contact is Teresa Barnes or Leslie Smith. Telephone number is toll free (877) 588-2035 or fax statements (703) 588-2046.
Privacy Act of 1974; Systems of Records
The Defense Finance and Accounting Service (DFAS) is proposing to amend a system of records notice to its existing inventory of records systems subject to the Privacy Act of 1974, (5 U.S.C. 552A), as amended.
Implementation of the Office of OMB Guidance on Nonprocurement Debarment and Suspension
The Department of Health and Human Services (``HHS'' or the ``Department'') adopted, by an interim final rule, the Office of Management and Budget (OMB) guidance at 2 CFR part 180 on nonprocurement debarment and suspension including some provisions specific to HHS. Public comment on this action was solicited in a Federal Register notice dated March 1, 2007. No comments were received; therefore, the Department makes no changes to its interim final rule and it remains in effect as of March 1, 2007. Pursuant to the requirements in OMB guidance, HHS makes final the following regulatory actions: Removes its existing regulation on nonprocurement debarment at 45 CFR part 76, establishes a new part 376 in title 2 Code of Federal Regulations (CFR) adopting OMB's guidance and adding provisions specific to HHS, and revises the reference in 45 CFR 74.13 to reflect the new citation to 2 CFR part 376.
36(b)(1) Arms Sales Notification
The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104-164 dated 21 July 1996.
Application of Inter Island Airways, Inc. d/b/a Inter Island Air for Commuter Authority
The Department of Transportation is directing all interested persons to show cause why it should not issue an order finding Inter Island Airways, Inc. d/b/a Inter Island Air fit, willing, and able, and awarding it Commuter Air Carrier Authorization.
National Information Assurance Program
Section 933 of Pub. L. 109-364, the John Warner National Defense Authorization Act for Fiscal Year 2007, provides that the Director, National Security Agency, may collect charges for evaluating, certifying, or validating information assurance products under the National Information Assurance Program (NIAP) or successor program. Table A sets forth the Fee-For-Service rates that will be assessed to NIAP accredited commercial Common Criteria Testing Labs (CCTLs) for ``validation'' services performed by NIAP validator personnel on information technology (IT) security products being evaluated by the NIAP CCTLs pursuant to the Common Criteria Evaluation and Validation Scheme (CCEVS).
Advisory Committee Meetings
The Defense Science Board 2007 Summer Study on Challenges to Military Operations in Support of National Interests will meet in closed session on August 6-16, 2007; at the Beckman Center, Irvine, CA. The mission of the Defense Science Board is to advise the Secretary of Defense and the Under Secretary of Defense for Acquisition, Technology & Logistics on scientific and technical matters as they affect the perceived needs of the Department of Defense. At this meeting, the Board will review previous and ongoing studies regarding stressing wars; identify defining parameters for challenges to military operations; assess capability gaps; and identify possible solutions. In accordance with section 10(d) of the Federal Advisory Committee Act, Pub. L. 92-463, as amended (5 U.S.C. App. 2) and 41 CFR 102-3.155, the Department of Defense has determined that these Defense Science Board Summer Study meeting will be closed to the public. Specifically, the Under Secretary of Defense (Acquisition, Technology and Logistics), with the coordination of the DoD Office of General Counsel, has determined in writing that all sessions of these meetings will be closed to the public because they will be concerned throughout with matters listed in 5 U.S.C. 552b(c)(1). Interested persons may submit a written statement for consideration by the Defense Science Board, Individuals submitting a written statement must submit their statement to the Designated Federal Official at the address detailed below, at any point, however, if a written statement is not received at least 10 calendar days prior to the meeting, which is the subject of this notice, then it may not be provided to or considered by the Defense Science Board. The Designated Federal Official will review all timely submissions with the Defense Science Board Chairperson, and ensure they are provided to members of the Defense Science Board before the meeting that is the subject of this notice.
Nonprocurement Debarment and Suspension
The Department of Defense (DoD) is revising the DoD Grant and Agreement Regulations (DoDGARs) to adopt and implement Office of Management and Budget (OMB) guidance on nonprocurement suspension and debarment and to make needed technical corrections. DoD is adopting and implementing the OMB guidance in a new part in title 2 of the CFR, the Governmentwide title recently established for OMB guidance and agencies' implementing regulations on grants and agreements. The Department also is removing the common rule on nonprocurement suspension and debarment that is in 32 CFR, Chapter I, Subchapter C, since the common rule is superseded by the new part implementing the OMB guidance. Adopting and implementing the OMB guidance and removing the common rule completes the DoD actions that the OMB guidance specifies. This regulatory action also is the first step toward relocating all of the DoDGARs to 2 CFR.
Findings of Scientific Misconduct
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Joy Bryant, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Joy Bryant, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755. Specifically, Ms. Bryant falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10-15 child participants in the TEAL study. Ms. Bryant has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) to exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Findings of Scientific Misconduct
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Diana Layman, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Diana Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755. Specifically, Ms. Layman falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10-15 child participants in the TEAL study. Ms. Layman has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Veterans' Advisory Board on Dose Reconstruction
Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the Government Act of 1976 (5 U.S.C. 552b, as amended) the Defense Threat Reduction Agency (DTRA) and the Department of Veterans Affairs (VA) announce the following advisory board meeting: Name of Committee: Veterans' Advisory Board on Dose Reconstruction (VBDR). Dates of Meeting: September 19-20, 2007. Location: Jesse Brown VA Medical Center, Multi Conference Center B and C, Room 2446, 820 S. Damen Ave., Chicago, Illinois 60612. Time: Wednesday, September 19, 2007, from 8:30 a.m.-12:30 p.m. and 2:30-5:15 p.m. with a public comment session from 1:30-2:30 p.m., and Thursday, September 20, 2007, from 8:30-11 a.m. and 12:15-12:45 p.m. with a public comment session from 11:15 a.m.-12:15 p.m. Purpose of Meeting: To obtain, review and evaluate information related to the Board mission to provide guidance and oversight of the dose reconstruction and claims compensation programs for veterans of U.S.-sponsored atmospheric nuclear weapons tests from 1945-1962; veterans of the 1945-1946 occupation of Hiroshima and Nagasaki, Japan; and veterans who were prisoners of war in those regions at the conclusion of World War II. In addition, the advisory board will assist the VA and DTRA in communicating with the veterans. Meeting Agenda: On Wednesday, the meeting will open with an introduction of the Board. The following briefings will be presented: ``A Review of Probability of Causation and Its Use in a Compensation Scheme for Nuclear Industry Workers in the United Kingdom'' by Dr. Richard Wakeford; ``An Atomic Veterans Experience on Nuclear Weapons Tests in 1958'' by Mr. John C. Taschner; ``Revised Quality Plan for the NTPR Enterprise'' by Dr. Richard Toohey; ``Status of the Jackson VA Regional Office'' by Ms. Carol Sullivan and Ms. Laraine Borden; ``A Report from Subcommittee 5 on Alternative Methods for Dose Reconstruction'' by Dr. Ronald Blanck; ``NTPR Dose Reconstruction and Veterans Communication Activities'' by Dr. Paul Blake; and ``VA Radiation Claims Compensation Program for Veterans'' by Mr. Thomas Pamperin. On Thursday, the four subcommittees established during the inaugural VBDR session will report on their activities since March 2007. The subcommittees are the ``Subcommittee on DTRA Dose Reconstruction Procedures'', the ``Subcommittee on VA Claims Adjudication Procedures'', the ``Subcommittee on Quality Management and VA Process Integration with DTRA Nuclear Test Personnel Review Program'', and the ``Subcommittee on Communication and Outreach.'' The Board will close with a discussion of the Subcommittee reports, future business and meeting dates. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 102-3.165, and the availability of space this meeting is open to the public. Seating is limited by the size of the meeting room. All persons must sign in legibly at the registration desk. Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102- 3.140(c), interested persons may submit a written statement for consideration by the Veterans' Advisory Board on Dose Reconstruction. Written statements should be no longer than two type-written pages and must address: The issue, discussion, and recommended course of action. Supporting documentation may also be included as needed to establish the appropriate historical context and to provide any necessary background information. Individuals submitting a written statement must submit their statement to the Board at 7910 Woodmont Ave., Suite 400, Bethesda, MD 20814-3095, at any point; however, if a written statement is not received at least 10 calendar days prior to the meeting, which is the subject of this notice, then it may not be provided to or considered by the Veterans' Advisory Board on Dose Reconstruction until its next open meeting. The Chairperson will review all timely submissions with the Designated Federal Officer, and ensure they are provided to members of the Veterans' Advisory Board on Dose Reconstruction members before the meeting that is the subject of this notice. After reviewing the written comments, the Chairperson and the Designated Federal Officer may choose to invite the submitter of the comments to orally present their issue during an open portion of this meeting or at a future meeting. The Chairperson, in consulting with the Designated Federal Officer, may, if desired, allot a specific amount of time for members of the public to present their issues for review and discussion by the Veterans' Advisory Board on Dose Reconstruction. Public Comments: The September 19-20, 2007 meeting is open to the public, approximately one hour each day will be reserved for public comments on issues related to the task of the Veterans' Advisory Board on Dose Reconstruction, and speaking time will be assigned on a first- come, first-served basis. The amount of time per speaker will be determined by the number of requests received, but is nominally five minutes each. All persons who wish to speak at the meeting must sign in legibly at the registration desk. Questions from the public will not be considered during this period. Speakers who wish to expand on their oral statements are invited to submit written statements to the Veterans' Advisory Board on Dose Reconstruction at 7910 Woodmont Ave., Suite 400, Bethesda, MD 20814-3095.
Findings of Research Misconduct
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Carlos A. Murillo, M.D., University of Texas Medical Branch at Galveston: Based on the report of an inquiry conducted by the University of Texas Medical Branch at Galveston (UTMB) and additional analysis and information obtained by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Carlos A. Murillo, M.D., former Surgical Resident, Department of Surgery, UTMB, engaged in research misconduct in research supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grants R01 DK48498 and T32 DK07639. Specifically, Dr. Murillo falsified research on the amelioration by antisense RNA (siRNA) of dextran-induced colonic toxicity in mice. He altered the concentrations of dextran solution fed to mice to induce colonic inflammation, by intentionally including little or no dextran in the drinking water of siRNA treated mice, so that the animals that received siRNA would have few or no colonic lesions. Dr. Murillo has entered into a Voluntary Exclusion Agreement (Agreement) in which he has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) That any institution that submits an application for PHS support for a research project on which Dr. Murillo's participation is proposed or that uses him in any capacity on PHS support research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to the funding agency for approval; the supervisory plan must be designed to ensure the scientific integrity of Dr. Murillo's research contribution; Dr. Murillo agrees to ensure that a copy of the supervisory plan is also submitted to ORI by the institution and agrees that he will not participate in any PHS-supported research until such a supervision plan is submitted to ORI; (2) to exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (3) to request retraction of the abstract entitled ``Inhibition of Phosphoinositol 3-kinase Using Anti-p85 siRNA Attenuates Dextran- Sulfate-Induced Inflammatory Bowel Disease'' (Gastroenterology 126:A49, 2004), by signing the letter of retraction prepared by ORI attached as Attachment 2 and made part of the Agreement.
Establishment of the National Biodefense Science Board
The Office of the Secretary announces establishment of the National Biodefense Science Board. The Board will provide expert advice and guidance to the Secretary on scientific, technical and other matters of special interest to the Department of Health and Human Services regarding activities to prevent, prepare for and respond to adverse health effects of public health emergencies resulting from current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate. Resumes or curricula vitae from qualified individuals who wish to be considered for membership on the Board are currently being accepted. To Submit a resume or curriculum vitae, send e-mail to nbsbnominations@hhs.gov.
Nationwide TRICARE Demonstration Project
The Demonstration is also referred to as the Operation Noble Eagle/Enduring Freedom Reservist and National Guard Benefits Demonstration. This notice is to advise interested parties of the continuation of the Demonstration in which the DoD Military Health System addresses unreasonable impediments to the continuity of healthcare encountered by certain family members of Reservists and National Guardsmen called to active duty in support of a Federal/ contingency operation. The Demonstration scheduled to end on October 31, 2007, is now extended through October 31, 2008.
Conscientious Objectors
This document removes part 75, ``Conscientious Objectors'' presently in Title 32 of the Code of Federal Regulations. The document on which this part was based has been revised and is limited only to DoD personnel management matters, affects only DoD military personnel, and has no impact on the public.
Job Corps: Preliminary Finding of No Significant Impact (FONSI) for the Proposed Job Corps Center To Be Located North of Roosevelt Highway Between Washington Road and Interstate 285 in College Park, GA
Pursuant to the Council on Environmental Quality Regulations (40 CFR part 1500-08) implementing procedural provisions of the National Environmental Policy Act (NEPA), the Department of Labor, Office of the Secretary (OSEC), in accordance with 29 CFR 11.11(d), gives notice that an Environmental Assessment (EA) has been prepared for a proposed new Job Corps Center to be located in College Park, Georgia, and that the proposed plan for a new Job Corps Center will have no significant environmental impact. This Preliminary Finding of No Significant Impact (FONSI) will be made available for public review and comment for a period of 30 days.
Exxon Valdez Oil Spill Trustee Council; Notice of Meeting
The Department of the Interior, Office of the Secretary is announcing a public meeting of the Exxon Valdez Oil Spill Public Advisory Committee.
36(b)(1) Arms Sales Notification
The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104-164 dated 21 July 1996.
Department of the Interior Implementation of OMB Guidance on Nonprocurement Debarment and Suspension
The Department of the Interior (Department) proposes to remove its regulations implementing the government-wide common rule on nonprocurement debarment and suspension, and to adopt in their place the Office of Management and Budget's (OMB) guidance. This regulatory action would implement OMB's initiative to streamline and consolidate all federal regulations on nonprocurement debarment and suspension into one part of the CFR. The Department does not intend to modify any of its current policy.
TRICARE Over-the-Counter Drug Demonstration Project
This notice is to advise interested parties of a demonstration project in which the Department of Defense will evaluate allowing selected over-the-counter (OTC) drugs to be included on the TRICARE uniform formulary. The Secretary will evaluate the costs/benefits and beneficiary satisfaction of providing OTC drugs under the pharmacy benefits program when the selected OTC drugs are determined to be clinically effective. The demonstration project will be available for beneficiaries within the United States, Puerto Rico, Virgin Islands, and Guam.
Proposed Collection; Comment Request
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Defense Finance and Accounting Service announces the proposed extension of a public information collection and seeks public comment on the provisions thereof. Comments are invited on : (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed information collection; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the information collection on respondents, including through the use of automated collection techniques or other forms of information technology.
DoD Freedom of Information Act (FOIA) Program
The Department of Defense is proposing to update current policies and procedures to reflect the DoD FOIA Program as prescribed by Executive Order 13392. The proposed changes will ensure appropriate agency disclosure of information, and offer consistency with the with the goals of section 552 of title 5, United States Code.
Combating Exploitive Child Labor Through Education in Bolivia, Cambodia, Colombia, the Democratic Republic of the Congo, the Dominican Republic, Indonesia, Morocco, the Philippines, Togo, and Uganda
The U.S. Department of Labor, Bureau of International Labor Affairs, will award up to USD 46.494 million through 10 or more Cooperative Agreements to one or more qualifying organizations and/or Associations to combat exploitive child labor in the following 10 countries: Bolivia (up to $3.344 million), Cambodia (up to $4 million), Colombia (up to $5.1 million), Democratic Republic of the Congo (up to $5.5 million), the Dominican Republic (up to $4 million), Indonesia (up to $5.55 million), Morocco (up to $3 million), the Philippines (up to $5.5 million), Togo (up to $5 million), and Uganda (up to $5.5 million). Projects funded under this solicitation will seek to sustainably withdraw and prevent children from entering exploitive labor through the provision of direct educational services and other project interventions, and ensure direct beneficiaries' enrollment, retention, and completion of the education and/or training program(s) in which they are enrolled. Projects will also seek to build capacity in target countries to eliminate exploitive child labor and promote educational alternatives for children. Projects funded aim to complement and expand upon existing projects and programs aimed at eliminating exploitive child labor, particularly the worst forms of child labor, and improving basic education in the target countries. Applicants must respond to the entire Scope of Work outlined in this solicitation for each country for which an application is submitted.
Office of the Secretary of Defense (Health Affairs)/TRICARE Management Activity
This notice is to advise interested parties of a Military Health System (MHS) demonstration project entitled Disease Management Demonstration Project for TRICARE Standard Beneficiaries. Although there are many similarities between TRICARE Standard and TRICARE Prime as to the preventive health care services that may be provided in the current benefit, there are services that are expressly excluded under TRICARE Standard that may be offered under TRICARE Prime which are the essence of a disease management (DM) program. TRICARE currently requires the Managed Care Support Contractors (MCSCs) to provide ``disease management services'' under the current contracts, without specific guidance. Based upon the current legal statutes authorizing preventive health care services, TRICARE must conduct a demonstration under 10 U.S.C. 1092 in order to offer TRICARE Prime benefits to TRICARE Standard beneficiaries under the DM program already in existence. (Section 734 of the John Warner National Defense Authorization Act for Fiscal Year 2007 (henceforth NDAA 2007) does not give any broader authority than exists today). Under this demonstration, disease management services will be provided to TRICARE Standard beneficiaries as part of the current MHS DM programs. The demonstration project will enable the MHS to provide uniform policies and practices on disease and chronic care management throughout the TRICARE network. Additionally, the demonstration will help determine the effectiveness of DM programs in improving the health status of beneficiaries with targeted chronic diseases or conditions, and any associated cost savings.
36(b)(1) Arms Sales Notification
The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104-165 dated 21 July 1996.
36(b)(1) Arms Sales Notification
The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104-164 dated 21 July 1996.
Meeting of the President's Commission on Care for America's Returning Wounded Warriors
Pursuant to section 10(a), Public Law 92-463, as amended, notice is hereby given of a forthcoming Meeting of the President's Commission on Care for America's Returning Wounded Warriors on 29 June 2007. The purpose of the Commission meeting is to conduct briefings for the Commissioners. The meeting is open to the public, subject to the availability of space. Interested persons may submit a written statement for consideration by the Committee and make an oral presentation of such. Persons desiring to make an oral presentation or submit a written statement to the Commission must notify the point of contact listed below no later than 5 p.m. 26 June 2007. Oral presentations by members of the public will be permitted only on 29 June from 2-2:30 p.m. before the full Committee. Presentations will be limited to 5 minutes. The Executive Director and the Designated Federal Official will select individuals for oral presentations and notify them in advance of the opportunity to make a 5 minute presentation to the Commission. Number of oral presentations to be made will depend on the number of requests received from members of the public. Each person desiring to make an oral presentation must provide the point of contact listed below with one (1) copy of the presentation by 26 June 2007, 5 p.m. and one copy of any material that is intended for distribution at the meeting. The Staff Points of Contact are Col. Denise Dailey, Major Teresa Barnes or Leslie Smith, toll free (877) 588-2035 or fax statements (703) 588- 2046.
Findings of Research Misconduct
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Wei Jin, Colorado State University: Based on an investigation conducted by Colorado State University (CSU) and additional analysis and information obtained by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Mr. Wei Jin, former doctoral candidate, Department of Chemistry, CSU, engaged in research misconduct in research funded by National Cancer Institutes (NCI), National Institutes of Health (NIH), grant R01 CA85419. Specifically, Mr. Jin falsified data/results by claiming he had performed a novel total synthesis of renieramycin G, when in fact, he obtained renieramycin G through a relatively simple reaction sequence from renieramycin M, a natural product that was a gift to the laboratory and that had been isolated by others from the Thai sponge. Mr. Jin included the falsified data/results in: His research notebooks and other records of his research; His dissertation, ``Asymmetric total synthesis of (-)- Reineramycin G and studies toward the total synthesis of Ecteinascidin- 743''; A manuscript, Jin, W. & Williams, R., ``Asymmetric total synthesis of (-)-Renieramycin G,'' accepted by the Journal of the American Chemical Society; and Supplemental information relative to the manuscript to be published online. ORI has implemented the following administrative actions for a period of three (3) years, beginning on May 8, 2007: (1) Mr. Jin is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ``covered transactions'' as defined in HHS' implementation of OMB Guidelines to Agencies on Government-wide Debarment and Suspension at 2 CFR Part 376, et seq.; and (2) Mr. Jin is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Request for Public Comments and Office of Management and Budget (OMB) Approval of an Existing Information Collection (2105-0551)
This notice requests public participation in the Office of Management and Budget approval process for the renewal of an existing OST information collection. In compliance with the Paperwork Reduction Act of 1995, this notice announces that the Information Collection Request (ICR) described below has been forwarded to OMB for extension of the currently approved collection. The ICR describes the nature of the information and the expected burden. OST published a Federal Register notice soliciting comments on the following collection of information and received none. The purpose of this notice is to allow the public an additional 30 days from the date of this notice to submit comments and to make a correction to the recently published application to renew ICR 2105-0551, ``Reporting Requirements for Disability-Related Complaints.''
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.